United Therapeutics scores another FDA approval

United Therapeutics Corp. can add another regulatory thumbs-up to its growing collection. The Silver Spring biotech has earned Food and Drug Administration approval for another use of Orenitram, a pulmonary arterial hypertension drugs first approved in 2013 to improve patients’ ability to exercise. The agency’s new stamp means the drug’s label can now reflect that it delays the d isease’s progression when used with another type of PAH therapy, United Therapeutics (NASDAQ: UTHR) said Monday. In…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news